A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/27/2018 |
| Start Date: | December 3, 2012 |
| End Date: | December 2022 |
| Contact: | Diana Trask, BS |
| Email: | trask@humonc.wisc.edu |
| Phone: | 608-263-9528 |
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27
fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until
time of progression in patients with recurrent high grade gliomas (grade III and grade IV).
Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior
exposure to bevacizumab.
fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until
time of progression in patients with recurrent high grade gliomas (grade III and grade IV).
Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior
exposure to bevacizumab.
Inclusion Criteria:
- Histologically confirmed diagnose of a grade WHO grade III or IV glioma
- Recurrent disease based on combination of clinical, imaging or histologic confirmation
- Must have previously received radiation and temozolomide to treat their glioma
- Bevacizumab naive patients must be > 6months post completion of initial radiation
therapy
- Bevacizumab exposed patients must be > 3months post completion of initial radiation
therapy
- Age must be >18years, KPS must be greater than 60
- Hematology, chemistry and a urinalysis must meet protocol specified criteria
Exclusion Criteria:
- Pregnant or breastfeeding
- May not be on full dose anti-coagulation therapy, Low molecular weight heparin is ok
- Uncontrolled hypertension (>140/90mmHg)
- Prior malignancy unless treated >1 year prior to study and have been without treatment
and disease free for 1 yr
- active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
We found this trial at
1
site
600 Highland Ave
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Steve Howard, MD
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Click here to add this to my saved trials
